LY-264086

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameLY-264086
Drug Alias NameLY-264086
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionLeukotriene B4 receptor antagonistsCyclooxygenases inhibitors
TargetsCyclooxygenasesLeukotriene B4 receptor
Therapy Area/IndicationsInflammationPsoriasisAsthma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesEli Lilly And Company
Active IndicationsN/A
Inactive IndicationsInflammationPsoriasisAsthma

Other Information

ATC CodeN/A
Related LinksN/A